Q1 2025 13F Holders as of 3/31/2025
-
Type / Class
-
Equity / Common Stock, $0.0001 par value per share
-
Shares outstanding
-
4.54M
-
Number of holders
-
45
-
Total 13F shares, excl. options
-
9.56M
-
Shares change
-
+2.69M
-
Total reported value, excl. options
-
$206M
-
Value change
-
+$57.6M
-
Number of buys
-
26
-
Number of sells
-
-11
-
Price
-
$21.54
Significant Holders of Cidara Therapeutics, Inc. - Common Stock, $0.0001 par value per share (CDTX) as of Q1 2025
48 filings reported holding CDTX - Cidara Therapeutics, Inc. - Common Stock, $0.0001 par value per share as of Q1 2025.
Cidara Therapeutics, Inc. - Common Stock, $0.0001 par value per share (CDTX) has 45 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 9.56M shares
.
Largest 10 shareholders include RA CAPITAL MANAGEMENT, L.P. (1.09M shares), VR ADVISER, LLC (1.05M shares), TCG Crossover Management, LLC (1.01M shares), ADAGE CAPITAL PARTNERS GP, L.L.C. (990K shares), BVF INC/IL (925K shares), Bain Capital Life Sciences Investors, LLC (703K shares), Vivo Capital, LLC (684K shares), VANGUARD GROUP INC (510K shares), Vestal Point Capital, LP (505K shares), and SUSQUEHANNA INTERNATIONAL GROUP, LLP (342K shares).
This table shows the top 45 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.